Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
DSIP vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
DSIP is distinguished by dSIP is a sleep-associated nonapeptide whose name overstates the human evidence; old intravenous insomnia studies were tiny and inconsistent, and no FDA-approved formulation or subcutaneous program exists; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
DSIP is distinguished in the current record by dSIP is a sleep-associated nonapeptide whose name overstates the human evidence; old intravenous insomnia studies were tiny and inconsistent, and no FDA-approved formulation or subcutaneous program exists. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceDSIP
DSIP: Mixed and very limited human evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
DSIP: Not FDA approved; July 2026 PCAC voted narrowly against 503A listing. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
DSIP
- Chronic insomnia
- Sleep architecture and daytime performance
- Opioid and alcohol withdrawal
- Narcolepsy — single-case historical evidence
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
DSIPNot FDA approved; PCAC voted no
Not FDA approved. On July 24, 2026, PCAC reportedly voted 6-7 with one abstention against recommending emideltide for the 503A Bulks List; the vote is nonbinding and is not a drug-approval decision.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
DSIPOld, tiny, conflicting studies
Several tiny controlled or externally controlled IV sleep studies, two uncontrolled opioid-withdrawal reports, one small anesthesia pharmacodynamic study, and broader preclinical mechanism research.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
DSIPNo controlled evidence
No controlled human evidence for weight loss, appetite control, body recomposition, or metabolic treatment was located.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
DSIPNo controlled evidence
No controlled human diabetes or glycaemic-outcome program was located.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
DSIPNo OSA evidence
No controlled human obstructive-sleep-apnoea outcome study was located. Chronic-insomnia findings cannot be transferred to OSA.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
DSIPNo outcomes program
No cardiovascular outcomes program exists. A small anesthesia study found increased heart rate and reduced heart-rate variability acutely.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
DSIPHistorical IV research only
Human research primarily used intravenous exposure. FDA found no effectiveness, pharmacokinetic, or safety data for the nominated subcutaneous route.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether any formulation or route provides reproducible sleep benefit and what formulation-specific pharmacokinetics, interactions, immunogenicity, abuse potential, and long-term safety look like.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
DSIP
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.